Genetic Testing in Patients with Autoimmune Lymphoproliferative Syndrome: Experience of 802 Patients at Cincinnati Children’s Hospital Medical Center

• Published in: Journal of clinical immunology 2024-10, Vol.44 (7), p.166, Article 166
• Main Authors: Xu, Xinxiu, Denton, James, Wu, Yaning, Liu, Jie, Guan, Qiaoning, Dawson, D. Brian, Bleesing, Jack, Zhang, Wenying
• Format: Article
• Language: English
• Subjects: Adolescent; Apoptosis; Autoimmune Lymphoproliferative Syndrome - diagnosis; Autoimmune Lymphoproliferative Syndrome - genetics; Biomedical and Life Sciences; Biomedicine; Child; Child, Preschool; CTLA-4 protein; Diagnosis; Family studies; fas Receptor - genetics; Female; Genetic disorders; Genetic Predisposition to Disease; Genetic screening; Genetic testing; Genetic Testing - methods; High-Throughput Nucleotide Sequencing; Hospitals, Pediatric; Humans; Immunodeficiency; Immunology; Infant; Infectious Diseases; Internal Medicine; Lymphadenopathy; Lymphocytes; Lymphoma; Male; Medical Microbiology; Mutation - genetics; Patients; Phenotypes; Splenomegaly
• ISSN: 0271-9142; 1573-2592; 1573-2592
• DOI: 10.1007/s10875-024-01772-z

Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder featuring chronic lymphadenopathy, splenomegaly, cytopenias, and increased lymphoma risk. Differentiating ALPS from immunodeficiencies with overlapping symptoms is challenging. This study evaluated the performance and the diagnostic yield of a 15-gene NGS panel for ALPS at Cincinnati Children’s Hospital Medical Center. Samples from 802 patients submitted for ALPS NGS panel were studied between May 2014 and January 2023. A total of 62 patients (7.7%) had a definite diagnosis: 52/62 cases (84%) showed 37 unique pathogenic/likely pathogenic germline FAS variants supporting ALPS diagnosis (6.5%, 52/802). The ALPS diagnostic yield increased to 30% in patients who additionally fulfilled abnormal ALPS immunology findings criteria. 17/37 (46%) diagnostic FAS variants were novel variants reported for the first time in ALPS. 10/802 cases (1.2%) showed diagnostic findings in five genes ( ADA2 , CTLA4 , KRAS , MAGT1 , NRAS ) which are related to autoimmune lymphoproliferative immunodeficiency (ALPID). Family studies enabled the reclassification of variants of unknown significance (VUS) and also the identification of at-risk family members of FAS -positive patients, which helped in the follow-up diagnosis and treatment. Alongside family studies, complete clinical phenotypes and abnormal ALPS immunology and Fas-mediated apoptosis results helped clarify uncertain genetic findings. This study describes the largest cohort of genetic testing for suspected ALPS in North America and highlights the effectiveness of the ALPS NGS panel in distinguishing ALPS from non-ALPS immunodeficiencies. More comprehensive assessment from exome or genome sequencing could be considered for undefined ALPS-U patients or non-ALPS immunodeficiencies after weighing cost, completeness, and timeliness of different genetic testing options.